首页> 美国卫生研究院文献>Oncology Letters >Evaluation of MMP-2 MMP-9 TIMP-1 TIMP-2 NGAL and MMP-9/NGAL complex in urine and sera from patients with bladder cancer
【2h】

Evaluation of MMP-2 MMP-9 TIMP-1 TIMP-2 NGAL and MMP-9/NGAL complex in urine and sera from patients with bladder cancer

机译:膀胱癌患者尿液和血清中MMP-2MMP-9TIMP-1TIMP-2NGAL和MMP-9 / NGAL复合物的评估

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The identification of biomarkers in urine or serum samples from patients with bladder cancer is urgently required for the development of non-invasive methods for the diagnosis of bladder carcinoma and to facilitate follow-up surveillance, to combat the high progression and recurrence rates of this type of cancer. The current study measured the content of matrix metalloproteinase (MMP)-2 and -9, as well as tissue inhibitor of metalloproteinase (TIMP)-1 and -2 in the urine and sera of 41 patients with bladder cancer by ELISA. The association between levels of MMP-2 and -9 and TIMP-1 and -2, and tumor grade and stage were investigated to verify whether these molecules are involved in tumor differentiation. Statistical analysis of the data revealed that urinary TIMP-1 levels were significantly higher in the high grade group compared with those of the low grade samples (P=0.022). The results also revealed a significantly differing distribution of TIMP-1 expression between Ta and T1 stage specimens (P=0.040). The corresponding area under the curves (AUCs) were 0.72, with a sensitivity of 0.70 and specificity of 0.75. In addition, neutrophil gelatinase-associated lipocalin (NGAL) and MMP-9/NGAL complex levels in the sera were measured. All molecules evaluated were detected in the sera of the patients studied. In particular, tumors staged as non-muscle invasive (Ta and T1), demonstrated significantly higher NGAL levels compared with those of muscle invasive (>T1) bladder cancer (32.8 ng/ml vs. 16.2 ng/ml; P=0.029). The discriminatory ability of NGAL expression was confirmed by receiver operating characteristic curve analysis that revealed an AUC of 0.75, a sensitivity of 0.88 and a specificity of 0.67. These data indicated that urinary TIMP-1 and serum NGAL may be useful non-invasive biomarkers to provide clinical information for bladder cancer disease management. Multicenter, prospective studies are required to confirm these preliminary results.
机译:迫切需要鉴定膀胱癌患者尿液或血清样品中的生物标志物,以开发诊断膀胱癌的非侵入性方法并促进后续监测,以对抗此类疾病的高进展和复发率癌症。当前的研究通过ELISA法测定了41例膀胱癌患者尿液和血清中基质金属蛋白酶(MMP)-2和-9的含量,以及金属蛋白酶组织抑制剂(TIMP)-1和-2的含量。研究了MMP-2和-9以及TIMP-1和-2的水平与肿瘤等级和分期之间的关联,以验证这些分子是否参与肿瘤分化。数据的统计分析表明,高等级组的尿TIMP-1水平明显低于低等级组(P = 0.022)。结果还显示,Ta和T1期标本之间TIMP-1表达的分布存在显着差异(P = 0.040)。曲线下的相应面积(AUC)为0.72,灵敏度为0.70,特异性为0.75。此外,还测量了血清中嗜中性粒细胞明胶酶相关的脂钙蛋白(NGAL)和MMP-9 / NGAL复合物的水平。在所研究患者的血清中检测到所有评估的分子。尤其是,分阶段为非肌肉浸润性肿瘤(Ta和T1)的NGAL水平明显高于肌肉浸润性膀胱癌(> T1)的NGAL水平(32.8 ng / ml对16.2 ng / ml; P = 0.029)。通过受体工作特性曲线分析证实了NGAL表达的区分能力,该分析表明AUC为0.75,灵敏度为0.88,特异性为0.67。这些数据表明,尿TIMP-1和血清NGAL可能是有用的非侵入性生物标志物,可为膀胱癌疾病的治疗提供临床信息。需要进行多中心前瞻性研究来确认这些初步结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号